USA – Surf Bio, a Palo Alto, CA-based biopharmaceutical company, raised $16M in Seed funding.
The round was led by Breakout Ventures and Perceptive Xontogeny Venture Fund.The company intends to use the funds advance its polymer-based drug delivery platform and accelerate the development of an ultra-rapid insulin for treatment of diabetes.Led by CEO Bryan Mazlish, Surf Bio is a preclinical biopharmaceutical company leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.In addition to its lead ultra-rapid insulin program, Surf Bio has established multiple, ongoing collaborations with multinational pharmaceutical companies. To date, demonstrated in-vitro and in-vivo safety and efficacy data has generated significant interest from partners to evaluate the company’s technology within their proprietary product pipelines. Proposed initial applications for the technology include increasing concentrations and reducing refrigeration dependence as well as enabling hard-to-formulate therapeutics.The Surf Bio Board of Directors will consist of current members and founders, Bryan Mazlish and Jennifer Schneider, MD, as well as new additions, Lindy Fishburne and Ben Askew, PhD.
13/04/2022
